The Xpert Bladder Cancer Monitor test is a urine-based molecular assay designed to help detect recurrent urothelial cancer in people who have already been diagnosed with bladder cancer. It measures messenger RNA from five genes—ABL1, CRH, IGF2, UPK1B, and ANXA10—and uses an automated algorithm to produce a qualitative result. The test is attractive because it uses voided urine and can be processed rapidly on the GeneXpert platform, without the subjective cell-shape interpretation required for urine cytology. Its result is still an adjunct, not a final diagnosis. A positive test increases concern for recurrence but does not show where a tumor is or prove cancer on its own. A negative result can be reassuring, particularly for high-grade recurrence, but low-grade tumors are easier to miss. Cystoscopy, pathology, cytology, previous tumor grade, treatment history, and the patient’s surveillance risk remain central to deciding what happens next.
- Xpert Bladder Cancer Monitor measures five urine mRNA targets associated with urothelial cancer.
- It is intended for recurrence surveillance rather than as a general cancer screening test for people with no bladder cancer history.
- A positive result raises the probability of recurrence but still requires clinical correlation and usually cystoscopic evaluation.
- A negative result is more reassuring for high-grade than low-grade recurrence because test sensitivity is grade dependent.
- The assay can complement cystoscopy and cytology, but current evidence does not support using it to replace surveillance universally.
Table of Contents
- What the Xpert Bladder Cancer Monitor Test Measures
- How the Urine Test Works
- What Positive, Negative, and Invalid Results Mean
- Accuracy for Bladder Cancer Recurrence
- Xpert Monitor Versus Cytology and Cystoscopy
- When the Test May Be Used in Surveillance
- Follow-Up After the Result
What the Xpert Bladder Cancer Monitor Test Measures
Xpert Bladder Cancer Monitor is an mRNA-based test. Messenger RNA is the temporary molecular copy cells use when genes are being expressed. Urothelial cancer changes gene-expression patterns, and the assay measures a selected group of transcripts in cells and cellular material present in urine.
The five targets are:
- ABL1
- CRH
- IGF2
- UPK1B
- ANXA10
These are not interpreted one by one as five separate cancer tests. The system measures the targets by reverse-transcription real-time PCR and combines the signal through the assay’s validated algorithm. The final clinical report is generally a qualitative call such as positive or negative, with an invalid result possible when quality requirements are not met.
The word Monitor is important. This version of the assay was developed for people with a previous diagnosis of bladder cancer, especially non-muscle-invasive bladder cancer undergoing surveillance. It should not be confused with an initial-detection assay or with broad urine tumor-marker screening. Test thresholds and intended-use populations can differ between product configurations and regulatory regions.
Because the assay measures gene expression rather than cell appearance, it differs fundamentally from the urine cytology test. Cytology asks whether cells look malignant; Xpert asks whether a five-gene expression pattern crosses the test algorithm’s threshold. The two tests can therefore disagree without either result being technically wrong.
How the Urine Test Works
The patient provides a voided urine sample, usually around the time of a surveillance visit. The specimen is mixed or transferred according to the laboratory’s validated collection protocol and loaded into a single-use cartridge compatible with the GeneXpert system. Much of the molecular process—sample preparation, reverse transcription, PCR amplification, signal detection, and calculation—is automated.
That automation is a practical strength. Traditional molecular testing can involve several manual extraction and amplification steps, increasing hands-on time and opportunities for variation. Cartridge-based testing standardizes much of the workflow and can generate a result much faster than tests that must be sent through more complex batch processing.
The assay does not search for one specific bladder cancer mutation. Instead, it looks for a combined expression pattern from the five messenger-RNA targets. The result therefore reflects a molecular signature associated with urothelial tumor cells in the urine. If insufficient usable molecular material is present or an internal quality criterion fails, the test may be reported as invalid rather than falsely labeled negative.
Collection quality still matters even with automation. Urine is a variable specimen: hydration, the number of cells shed, recent instrumentation, treatment, storage, and transport can affect the material available for analysis. Laboratories use defined preservation and handling instructions to reduce those sources of variability.
The assay also does not provide tumor stage or grade. A high molecular signal is not equivalent to muscle-invasive disease, and a low or negative signal is not proof that the bladder is tumor free. Grade-specific information comes from tissue when recurrence is resected or biopsied.
What Positive, Negative, and Invalid Results Mean
A positive Xpert Bladder Cancer Monitor result means that the measured mRNA pattern met the assay’s positive algorithm. In someone with a history of bladder cancer, this raises concern for recurrent urothelial carcinoma. It is a risk signal, not a pathologic diagnosis.
A positive result cannot tell the clinician:
- where a recurrence is located;
- whether a visible tumor is present at that moment;
- whether the lesion is low grade or high grade;
- how deeply a tumor invades the bladder wall;
- or whether the patient needs a particular treatment.
Those questions require cystoscopy, imaging in selected cases, and tissue diagnosis when a lesion is found. A molecular test can influence how urgently those investigations are pursued, but it does not replace them.
A negative result means the five-gene expression pattern did not reach the positive threshold. In surveillance studies, negative predictive value has often been high, especially for high-grade recurrence. That can make a negative result clinically useful in risk-adapted strategies. However, negative predictive value changes with recurrence prevalence, and sensitivity is not perfect.
Low-grade tumors are a particular limitation. They can be small, shed fewer abnormal cells, or produce a weaker molecular signature than aggressive tumors. A negative Monitor result therefore cannot guarantee the absence of a low-grade papillary recurrence. This distinction is important when patients hear that the test has “high sensitivity” without being told that performance varies by grade.
An invalid result means the assay could not produce a reliable positive/negative interpretation under its quality controls. It should not be read as reassuring. The laboratory may recommend recollection or repeat testing, but a patient with a concerning cystoscopy or symptoms should not delay necessary evaluation solely to obtain a repeat urine result.
Accuracy for Bladder Cancer Recurrence
The best current accuracy estimates come from pooled studies rather than one individual trial. A 2026 systematic review and meta-analysis evaluated 26 studies involving 8,613 patients across Xpert Detection and Monitor settings. For the Monitor cohorts, pooled sensitivity was 71% and specificity was 78%, with a negative predictive value of 91%. High-grade sensitivity was 80%, compared with about 60% for low-grade disease. The authors rated the certainty of several diagnostic estimates as low or very low, so the numbers should be treated as useful summaries rather than permanent universal constants.
An earlier 2021 meta-analysis of 11 prospective surveillance studies including 2,896 patients reported pooled sensitivity of 73% and specificity of 77%. In high-grade recurrence, sensitivity reached 86% in the subgroup analysis, whereas low-grade sensitivity was 58%. The consistency of that pattern across reviews is clinically important: Xpert Monitor tends to detect biologically higher-risk recurrence better than low-grade recurrence.
| Performance concept | What it means in surveillance |
|---|---|
| Sensitivity | How often the test is positive when recurrence is truly present |
| Specificity | How often the test is negative when recurrence is not present |
| Positive predictive value | Among positive tests, the probability that recurrence is actually present |
| Negative predictive value | Among negative tests, the probability that recurrence is absent |
Predictive values are not fixed properties of the assay. They depend on the population being tested. A patient with repeated high-grade tumors has a higher pretest probability of recurrence than a patient with a remote history of one low-risk lesion, so the same positive or negative molecular result can mean something different for each person.
Accuracy also changes with timing, treatment, definition of recurrence, and study design. A study that verifies every patient with cystoscopy and histology is not directly comparable with one using different follow-up rules. This is why a laboratory report should not be interpreted using a sensitivity figure taken from an unrelated patient population.
The 2026 pooled estimate also illustrates why a positive result is not diagnostic. With Monitor specificity around the high-70% range, some patients without confirmed recurrence will test positive. Conversely, an overall sensitivity near 70% means some true recurrences will be missed. The clinical value comes from shifting probability, particularly when the concern is high-grade disease, rather than from creating certainty. A clinician may accept different tradeoffs depending on whether the goal is to avoid an unnecessary cystoscopy in a low-risk patient or to avoid missing aggressive disease in a high-risk patient.
Xpert Monitor Versus Cytology and Cystoscopy
Cystoscopy remains the reference procedure for visual surveillance of the bladder. A flexible scope allows the urologist to inspect the mucosa directly and identify papillary tumors, suspicious red areas, scar tissue, and other abnormalities. If a lesion requires confirmation, transurethral resection or biopsy provides tissue for pathology.
Urine cytology is noninvasive and highly specific when clearly positive for high-grade urothelial carcinoma, but it has limited sensitivity for low-grade tumors and can produce atypical or suspicious categories. Xpert Monitor is more automated and often more sensitive than cytology in surveillance studies, but its specificity is lower than ideal and a positive result can occur without visible recurrence at that visit.
UroVysion offers another molecular adjunct. The UroVysion FISH test looks for gains of chromosomes 3, 7, and 17 or loss of 9p21 rather than measuring RNA expression. Neither assay is inherently “better” in every patient; they have different workflows, molecular targets, evidence bases, costs, and clinical roles.
The central tradeoff is between invasiveness and certainty. A urine test is easy for the patient but does not show the bladder or provide tissue. Cystoscopy is invasive but gives immediate anatomic information. The clinically useful goal is not simply to replace every cystoscopy. It is to determine whether validated biomarkers can safely reduce unnecessary procedures in selected lower-risk situations while preserving prompt detection of dangerous recurrence.
Recent systematic reviews of surveillance biomarkers support this complementary approach. Molecular tests may help risk-stratify follow-up, but heterogeneous studies and limited clinical-utility evidence prevent a one-size-fits-all substitution strategy.
When the Test May Be Used in Surveillance
Xpert Bladder Cancer Monitor may be considered during follow-up of previously diagnosed bladder cancer, especially non-muscle-invasive disease. Surveillance schedules are determined by previous tumor stage, grade, number, size, recurrence pattern, carcinoma in situ, treatment response, and other risk factors. High-risk patients generally require more intensive cystoscopic follow-up than low-risk patients.
A urine molecular result may be useful in several situations. It can provide additional information when cytology is atypical, when cystoscopy is negative but concern remains, or when a clinician is considering a risk-adapted schedule. Research has also examined whether negative molecular tests could help identify patients in whom some cystoscopies might safely be deferred, but such strategies require validated protocols rather than individual improvisation.
The 2025 VERNAL study specifically evaluated an mRNA-based urine test in high- and very-high-risk NMIBC patients during endoscopic follow-up. Studies like this are important because the safety threshold for reducing cystoscopy is much higher in people at meaningful risk of high-grade recurrence or progression.
The test is not designed to explain new hematuria in every person or to screen the general population. Someone with visible blood in the urine needs evaluation for the full range of possible causes, which can include infection, stones, benign prostate disease, kidney disorders, medications, and urinary tract cancer. A surveillance assay for previously diagnosed bladder cancer should not be substituted for a risk-based hematuria workup.
Treatment timing can also affect how a surveillance result is used. Patients may be tested after transurethral resection, during or after intravesical therapy, or at routine intervals months later. Those settings have different recurrence probabilities and potentially different sources of urinary cellular change. The ordering clinician should know when the specimen was collected relative to procedures and therapy before acting on the result.
Similarly, a patient should not order multiple urine biomarkers and treat agreement among them as proof. A broad urine tumor marker test panel contains tests with different intended uses, and combining unvalidated results can create more confusion rather than more certainty.
Follow-Up After the Result
After a positive Monitor result, the clinician reviews the patient’s recurrence risk and the timing of the next cystoscopy. If cystoscopy is already scheduled, it is usually completed rather than replaced by the urine result. A suspicious lesion is then resected or biopsied as appropriate. If cystoscopy is negative despite a positive molecular test, the urologist may consider earlier repeat evaluation, urine cytology, enhanced cystoscopy, or upper-tract assessment depending on the patient’s history.
A positive urine result with negative cystoscopy can be genuinely discordant. It may represent a false positive, molecular evidence that precedes visible recurrence, disease elsewhere in the urothelial tract, or biological/technical variation. No single explanation should be assumed without follow-up.
If discordance persists, the next investigation is selected according to risk rather than by repeating molecular testing indefinitely. Options can include repeat flexible cystoscopy, enhanced cystoscopic imaging, cytology, directed biopsy, or upper-tract imaging and endoscopy when clinically indicated. Previous carcinoma in situ is especially relevant because flat high-grade disease can be difficult to see. The urine result helps frame concern, while endoscopic and pathologic evaluation localize and confirm disease.
After a negative result, the key question is whether the patient belongs to a group in which a biomarker-guided surveillance pathway has been validated. For a high-risk patient, a negative test generally should not cancel required cystoscopy. For a lower-risk patient, clinicians may increasingly use urine biomarkers to tailor surveillance, but recommendations depend on local guidance and the exact assay indication.
Patients should also report new visible hematuria, persistent urinary urgency or burning, unexplained pelvic pain, or other concerning symptoms even if a recent molecular test was negative. Symptoms can alter the pretest probability and make direct evaluation more urgent.
The most practical way to discuss the report is to ask three questions: What was my recurrence risk before this test? How much does this result change that risk? What specific surveillance step changes because of it? Those questions keep the molecular result connected to the clinical decision it was designed to support.
References
– Xpert bladder cancer detection and monitor in urothelial carcinoma: systematic review and meta-analysis 2026 (Systematic Review) – Xpert® bladder Cancer monitor urine test for non-muscle-invasive bladder cancer surveillance: a prospective clinical trial 2026 (Prospective Study) – mRNA-Based Urine Test Performance in High and Very-High Risk Non-Muscle-Invasive Bladder Cancer Patients Undergoing Contextual Endoscopic Follow-up (VERNAL: Vesical Tumor Early Monitoring: mRNA-Based Follow-up) 2025 (Prospective Study) – Evaluating diagnostic performance of urinary biomarkers in the surveillance of non-muscle invasive bladder carcinoma: A systematic review 2025 (Systematic Review) – Urinary Biomarkers in Bladder Cancer: FDA-Approved Tests and Emerging Tools for Diagnosis and Surveillance 2025 (Review) – Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis. 2022 (Systematic Review)
Disclaimer
This article is for general educational information and does not provide medical advice, diagnosis, or treatment. Xpert Bladder Cancer Monitor results should be interpreted by a qualified urologic clinician in the context of cystoscopy, pathology, cytology, prior treatment, and recurrence risk. Do not change or skip a prescribed bladder cancer surveillance visit based on a urine test alone.
